Journal: Biomolecules

Article Title: Predictive and Prognostic Relevance of ABC Transporters for Resistance to Anthracycline Derivatives

doi: 10.3390/biom15070971

Figure Lengend Snippet: Resazurin cell viability assay. Dose–response curves of doxorubicin, daunorubicin, idarubicin, and aclarubicin with the sensitive CCRF-CEM and multidrug-resistant P-glycoprotein overexpressing CEM-ADR5000 leukemia cells for 72 h. The data represents the mean ± standard deviation from three independent experiments.

Article Snippet: The cell lines were treated with doxorubicin, daunorubicin, and idarubicin, which were provided by the University Medical Center of the Johannes Gutenberg University (Mainz, Germany), and with aclarubicin (HY-N2306) and pirarubicin (HY-13725), which were supplied by MedChemExpress, Monmouth Junction, NJ, USA).

Techniques: Viability Assay, Standard Deviation

Journal: Biomolecules

Article Title: Predictive and Prognostic Relevance of ABC Transporters for Resistance to Anthracycline Derivatives

doi: 10.3390/biom15070971

Figure Lengend Snippet: Live cell time-lapse imaging of CCRF-CEM and CEM/ADR5000 cells upon treatment with selected anthracyclines. ( A ) and show representative images of CCRF-CEM and CEM/ADR5000 cells treated with the indicated compounds (from top to bottom, daunorubicin ( 9 ), idarubicin ( 4 ), aclarubicin ( 7 ), and untreated cells). The results of CCRF-CEM cells are shown in the first row, and those for CEM/ADR5000 cells are shown in the second row. Fluorescent images and merged images of fluorescence signal and phase contrast are shown at 0 min, 15 min, 30 min, and 3 h after compound addition. The scale bar in merged images corresponds to 50 µm. ( B ) Quantification of cellular uptake of daunorubicin, idarubicin, and aclarubicin in CCRF-CEM cells (orange) and CEM/ADR5000 cells (green) was carried out by the built-in analysis module, and the average object mean intensity was plotted. Error bars show standard deviation of three biological replicates. Time lapses were acquired every 3 min for the first 0.5 h and every 15 min for the following 2.5 h. At each time point, daunorubicin and idarubicin were significantly accumulated at higher levels in CCRF-CEM cells compared to CEM/ADR5000 cells (unpaired t test, p < 0.0001), whereas aclarubicin accumulated at a similar level in both cell lines (the unpaired t test showed no significant difference, p > 0.0654).

Article Snippet: The cell lines were treated with doxorubicin, daunorubicin, and idarubicin, which were provided by the University Medical Center of the Johannes Gutenberg University (Mainz, Germany), and with aclarubicin (HY-N2306) and pirarubicin (HY-13725), which were supplied by MedChemExpress, Monmouth Junction, NJ, USA).

Techniques: Imaging, Fluorescence, Standard Deviation